These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36471030)

  • 1. End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.
    Morales AM; Sreedhara A; Buecheler J; Brosig S; Chou D; Christian T; Das T; de Jong I; Fast J; Jagannathan B; Moussa EM; Nejadnik MR; Prajapati I; Radwick A; Rahman Y; Singh S
    AAPS J; 2022 Dec; 25(1):6. PubMed ID: 36471030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations.
    Katz JS; Chou DK; Christian TR; Das TK; Patel M; Singh SN; Wen Y
    J Pharm Sci; 2022 Apr; 111(4):919-932. PubMed ID: 34883096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80?
    Bollenbach L; Buske J; Mäder K; Garidel P
    Int J Pharm; 2022 May; 620():121706. PubMed ID: 35367584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension to Predict Surfactant Requirements for Biological Formulations.
    Vargo KB; Stahl P; Hwang B; Hwang E; Giordano D; Randolph P; Celentano C; Hepler R; Amin K
    Mol Pharm; 2021 Jan; 18(1):148-157. PubMed ID: 33253579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
    Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
    Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of Polysorbates.
    Wuchner K; Yi L; Chery C; Nikels F; Junge F; Crotts G; Rinaldi G; Starkey JA; Bechtold-Peters K; Shuman M; Leiss M; Jahn M; Garidel P; de Ruiter R; Richer SM; Cao S; Peuker S; Huille S; Wang T; Le Brun V
    J Pharm Sci; 2022 May; 111(5):1280-1291. PubMed ID: 35192858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
    Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
    J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the Future.
    Wuchner K; Yi L; Chery C; Nikels F; Junge F; Crotts G; Rinaldi G; Starkey JA; Bechtold-Peters K; Shuman M; Leiss M; Jahn M; Garidel P; de Ruiter R; Richer SM; Cao S; Peuker S; Huille S; Wang T; Brun VL
    J Pharm Sci; 2022 Nov; 111(11):2955-2967. PubMed ID: 36002077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality.
    Das TK; Sreedhara A; Colandene JD; Chou DK; Filipe V; Grapentin C; Searles J; Christian TR; Narhi LO; Jiskoot W
    J Pharm Sci; 2022 Apr; 111(4):868-886. PubMed ID: 34563537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Impact of Surfactant Type and Digestion: Highly Digestible Surfactants Improve Oral Bioavailability of Nilotinib.
    Koehl NJ; Holm R; Kuentz M; Jannin V; Griffin BT
    Mol Pharm; 2020 Sep; 17(9):3202-3213. PubMed ID: 32649208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Surfactants on the Functionality of Prefilled Syringes.
    Wang T; Richard CA; Dong X; Shi GH
    J Pharm Sci; 2020 Nov; 109(11):3413-3422. PubMed ID: 32771345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A surfactant-stripped cabazitaxel micelle formulation optimized with accelerated storage stability.
    Sun B; Jing H; Mabrouk MT; Zhang Y; Jin H; Lovell JF
    Pharm Dev Technol; 2020 Dec; 25(10):1281-1288. PubMed ID: 32892678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Hydrophobic Tail Length Variation on Surfactant-Mediated Protein Stabilization.
    Hanson MG; Katz JS; Ma H; Putterman M; Yezer BA; Petermann O; Reineke TM
    Mol Pharm; 2020 Nov; 17(11):4302-4311. PubMed ID: 33054234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Properties of Novel Excipient Suggest Mechanism for Improved Performance in Liquid Stabilization of Protein Biologics.
    Katz JS; Nolin A; Yezer BA; Jordan S
    Mol Pharm; 2019 Jan; 16(1):282-291. PubMed ID: 30495962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the Stabilization of Interferon Alpha by Two Surfactants Revealed by STD-NMR Spectroscopy.
    Svilenov HL; Kopp KT; Golovanov AP; Winter G; Zalar M
    J Pharm Sci; 2023 Feb; 112(2):404-410. PubMed ID: 36257338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.
    Kanthe AD; Carnovale MR; Katz JS; Jordan S; Krause ME; Zheng S; Ilott A; Ying W; Bu W; Bera MK; Lin B; Maldarelli C; Tu RS
    Mol Pharm; 2022 Sep; 19(9):3100-3113. PubMed ID: 35882380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edetate Disodium as a Polysorbate Degradation and Monoclonal Antibody Oxidation Stabilizer.
    Yarbrough M; Hodge T; Menard D; Jerome R; Ryczek J; Moore D; Baldus P; Warne N; Ohtake S
    J Pharm Sci; 2019 Apr; 108(4):1631-1635. PubMed ID: 30502482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the Influence of Polysorbate 20/80 and Polaxomer P188 on the Surface & Interfacial Properties of Bovine Serum Albumin and Lysozyme.
    Begum F; Amin S
    Pharm Res; 2019 May; 36(7):107. PubMed ID: 31111248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Newly Identified Impurity in Polysorbate 80, the Long-Chain Ketone 12-Tricosanone, Forms Visible Particles in a Biopharmaceutical Drug Product.
    Hampl V; Guo X; Ehrenstrasser C; Viertler M; Rayner L; Campanelli G; Schipflinger R; Thewes K; Cerreti A; Boehm S; Sonderegger C
    J Pharm Sci; 2018 Jun; 107(6):1552-1561. PubMed ID: 29499279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.